Gemigliptin (a novel DPP4 inhibitor) might mitigate hepatic steatosis and IR, suggesting a direct protective effect on NAFLD progression, which inhibits the expression of LECT2 through AMPK-dependent and JNK-dependent mechanisms (36). The gene discussed is LECT2; the disease is Hepatic steatosis.